Peptide Comparison
Hexarelin vs Hulk Stack
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Hexarelin has stronger documented evidence (Phase 2 (not approved)) than Hulk Stack (Anecdotal) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Hexarelin | Hulk Stack | |
|---|---|---|
| Class | GHRP; potent ghrelin receptor agonist | GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; more potent GH release than other GHRPs | Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. |
| Route | SC / Intranasal | SC injection (typically 2-3 separate sites) |
| Half-life | ~1 hr | CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs |
| Dosage (research) | 100-200 mcg SC 1-2x daily (short cycles) | Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks |
| Evidence tier | Phase 2 (not approved) | Anecdotal |
| Research depth | 158 indexed | — |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Cortisol/prolactin elevation; pituitary desensitization | Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Hexarelin or Hulk Stack?
Hexarelin has stronger documented evidence (Phase 2 (not approved)) than Hulk Stack (Anecdotal) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Hexarelin and Hulk Stack?
Hexarelin is classed as GHRP; potent ghrelin receptor agonist; Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: Hexarelin, ~1 hr; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: Hexarelin, SC / Intranasal; Hulk Stack, SC injection (typically 2-3 separate sites).
Which has stronger evidence, Hexarelin or Hulk Stack?
Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, Hexarelin or Hulk Stack?
Neither Hexarelin nor Hulk Stack is an FDA-approved drug. Catalog status: Hexarelin, Research Chemical; Hulk Stack, Compounding Restricted.
Are Hexarelin and Hulk Stack ever combined?
Hexarelin and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…